Bleeding risk and reversal strategies for old and new anticoagulants and antiplatelet agents

被引:123
作者
Levi, M. [1 ,2 ]
Eerenberg, E. [1 ,2 ]
Kamphuisen, P. W. [1 ,2 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Med, NL-1105 AZ Amsterdam, Netherlands
关键词
anticoagulants; anti-IIa agents; anti-Xa agents; aspirin; hemorrhage; heparin; pentasaccharides; thienopyridine derivatives; vitamin K antagonists; FACTOR XA INHIBITOR; MOLECULAR-WEIGHT HEPARIN; ACUTE CORONARY SYNDROMES; DEEP-VEIN THROMBOSIS; COUMARIN-ASSOCIATED COAGULOPATHY; RECOMBINANT FACTOR VIIA; VITAMIN-K ANTAGONISTS; INTRACRANIAL HEMORRHAGE; VENOUS THROMBOEMBOLISM; DOUBLE-BLIND;
D O I
10.1111/j.1538-7836.2011.04432.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The most important adverse effect of antithrombotic treatment is the occurrence of bleeding. In the case of severe bleeding in a patient who uses anticoagulant agents or when a patient on anticoagulants needs to undergo an urgent invasive procedure, it may be useful to reverse anticoagulant treatment. Conventional anticoagulants such as vitamin K antagonists may be neutralized by administration of vitamin K or prothrombin complex concentrates, whereas heparin and heparin derivatives can be counteracted by protamine sulphate. The anti-hemostatic effect of aspirin and other antiplatelet strategies can be corrected by the administration of platelet concentrate and/or desmopressin, if needed. Recently, a new generation of anticoagulants with a greater specificity towards activated coagulation factors as well as new antiplatelet agents have been introduced and these drugs show promising results in clinical studies. A limitation of these new agents may be the lack of an appropriate strategy to reverse the effect if a bleeding event occurs, although experimental studies show hopeful results for some of these agents.
引用
收藏
页码:1705 / 1712
页数:8
相关论文
共 73 条
[1]   Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic [J].
Abdelhafiz, AH ;
Wheeldon, NM .
CLINICAL THERAPEUTICS, 2004, 26 (09) :1470-1478
[2]   Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939) - The ODIXa-DVT (oral direct factor Xa inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study [J].
Agnelli, Giancarlo ;
Gallus, Alexander ;
Goldhaber, Samuel Z. ;
Haas, Sylvia ;
Huisman, Menno V. ;
Hull, Russel D. ;
Kakkar, Ajay K. ;
Misselwitz, Frank ;
Schellong, Sebastian .
CIRCULATION, 2007, 116 (02) :180-187
[3]   Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial [J].
Alexander, John H. ;
Becker, Richard C. ;
Bhatt, Deepak L. ;
Cools, Frank ;
Crea, Filippo ;
Dellborg, Mikael ;
Fox, Keith A. A. ;
Goodman, Shaun G. ;
Harrington, Robert A. ;
Huber, Kurt ;
Husted, Steen ;
Lewis, Basil S. ;
Lopez-Sendon, Jose ;
Mohan, Puneet ;
Montalescot, Gilles ;
Ruda, Mikhail ;
Ruzyllo, Witold ;
Verheugt, Freek ;
Wallentin, Lars ;
Darius, Harald ;
Simoons, Maarten ;
Boersma, Eric ;
DeLemos, James ;
Spencer, Fred .
CIRCULATION, 2009, 119 (22) :2877-U39
[4]   Recurrent venous thrombosis and heparin therapy -: An evaluation of the importance of early activated partial thromboplastin times [J].
Anand, SS ;
Bates, S ;
Ginsberg, JS ;
Levine, M ;
Buller, H ;
Prins, M ;
Haley, S ;
Kearon, C ;
Hirsh, J ;
GEnt, M .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (17) :2029-2032
[5]   Pharmacology and management of the vitamin K antagonists [J].
Ansell, Jack ;
Hirsh, Jack ;
Hylek, Elaine ;
Jacobson, Alan ;
Crowther, Mark ;
Palareti, Gualtiero .
CHEST, 2008, 133 (06) :160S-198S
[6]   Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay [J].
Barrett, Yu Chen ;
Wang, Zhaoqing ;
Frost, Charles ;
Shenker, Andrew .
THROMBOSIS AND HAEMOSTASIS, 2010, 104 (06) :1263-1271
[7]   Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors [J].
Battistella, M ;
Mamdami, MM ;
Juurlink, DN ;
Rabeneck, L ;
Laupacis, A .
ARCHIVES OF INTERNAL MEDICINE, 2005, 165 (02) :189-192
[8]   Intravenous Platelet Blockade with Cangrelor during PCI. [J].
Bhatt, Deepak L. ;
Lincoff, A. Michael ;
Gibson, C. Michael ;
Stone, Gregg W. ;
McNulty, Steven ;
Montalescot, Gilles ;
Kleiman, Neal S. ;
Goodman, Shaun G. ;
White, Harvey D. ;
Mahaffey, Kenneth W. ;
Pollack, Charles V., Jr. ;
Manoukian, Steven V. ;
Widimsky, Petr ;
Chew, Derek P. ;
Cura, Fernando ;
Manukov, Ivan ;
Tousek, Frantisek ;
Jafar, M. Zubair ;
Arneja, Jaspal ;
Skerjanec, Simona ;
Harrington, Robert A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (24) :2330-2341
[9]   Prasugrel in Clinical Practice. [J].
Bhatt, Deepak L. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :940-942
[10]   Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives [J].
Bianchini, Elsa P. ;
Fazavana, Judicael ;
Picard, Veronique ;
Borgel, Delphine .
BLOOD, 2011, 117 (06) :2054-2060